Key facts: Novo Nordisk shares fall 8.3%; Wegovy faces competition — TradingView News
Novo Nordisk shares dropped 8.3% to 279.50 crowns after Hims & Hers launched a cheaper version of Wegovy. The company plans legal action, raising market concerns about competition.123Novo Nordisk’s Wegovy is used by one in eight U.S. adults, reducing sugar intake. The demand for GLP-1 drugs is rising, especially in G-20 nations, as patents expire.4Novo Nordisk expects a revenue drop in 2026 from pricing pressures, but plans to counter this with strict cost control and ongoing volume growth.5